3 research outputs found
Assessment of usage of Mobile Applications for self-care in Diabetic Patients attending dental OPD A preliminary study
No full textPakistani population is ranked number 3rd in the prevalence of diabetes after India and China. Its self-management has been considered a keystone for the care of the disease. It is imperative to take measures that can help diabetic patients to maintain self-management. Recent advancements in the field of information technology, such as digital applications, might help to create a platform for delivering and managing self-care interventions that would be easily accessible. Thus, this study was designed to evaluate the frequency of utilization of smartphone technology for self-care. A multi-centric, cross-sectional study was conducted. The results of the study showed that most patients use smartphones but only a few users were aware of health applications for self-care of diabetes. Most patients were using health applications for their self-management only when they are in need. In conclusion, most patients in Pakistan use smart phone but they do not utilise health care mobile applications appropriately due to the lack of awareness. Given the increasing number of patients it is essential to provide public health awareness regarding use of these applications so that patients can manage their glycaemic control at home with convenience. This will also reduce burden on health care system
Crosslinking Apigenin with Neurodevelopment: In-Vivo Model Designing based Therapeutic Strategy for Autism-Associated Neuroinflammation
No full textBackground: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by impaired social interaction, communication difficulties, and repetitive behaviors. Neuroinflammation is increasingly recognized as a key contributor to ASD pathophysiology. Nerve Growth Factor (NGF), a vital neurotrophin involved in neuronal survival and plasticity, is often dysregulated in ASD, exacerbating neurological dysfunction. Apigenin, a natural flavonoid with known anti-inflammatory and neuroprotective properties, has shown promise as a therapeutic agent in neurodevelopmental conditions. This study evaluated the effects of apigenin treatment on autism-like neuroinflammation by examining its impact on NGF regulation in a rodent model.
Methods: This in vivo study (July–November 2021) used 20 healthy male rats (8 weeks old). The research took place within the Animal House facility and was analyzed at SMDC Lahore and LUMHS Jamshoro, Sindh. Group I (n=4) was taken as control, while Groups II–V (n=16) received 250 mg/kg/day propionic acid (PPA) to induce autism-like neuroinflammation. Groups III–V were treated with Apigenin at 50, 100, and 200 mg/kg. NGF serum levels were analyzed using the enzyme-linked immunosorbent assay (ELISA). SPSS v 21 was used for statistical analysis using one-way ANOVA and Tukey’s test. p<0.05 was taken as significant.
Results: The levels of NGF were significantly lowered using propanoic acid (PPA) (4.3 ± 0.5 pg/mL vs control 11.9 ± 0.5). Apigenin dose-dependently restored NGF, with Group V (200 mg/kg) reaching 9.8 ± 0.5 pg/mL.
Conclusion: The neuroprotective properties of apigenin are evident through its ability to restore PPA-damaged levels of NGF, thus establishing potential use as an autism treatment for neuroinflammation in neurodevelopmental disorders
Evaluating Neurotherapeutic Potential of Naringenin by True Experiments: Insights into In-Vivo Psychiatry Care Models
No full textBackground: The brain function and development are impaired when psychiatric disorders cause neuroinflammation and neurotrophic dysregulation. This study aimed to evaluate the Naringenin\u27s neurotherapeutic potential utilizing controlled in vivo trials, with an emphasis on its function in controlling neuroinflammation and restoring neurotrophic balance in a psychiatric care model.
Methods: The in vivo experimental research took place during four months, from April 2021 to August 2021, utilizing 20 healthy male rats, aged eight weeks. Experiments were performed on animals at the Animal House, and biochemical analyses were carried out at SMDC Lahore and LUMHS Jamshoro. The subjects were divided into five groups: Group I (control) and Groups II–V, which received 250 mg/kg/day of propionic acid (PPA) to induce neuroinflammation that resembled psychiatric disorders. Naringenin was administered to Groups III–V at escalating doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg after PPA was induced for four weeks. The ELISA testing system measured Nerve Growth Factor (NGF) serum concentrations, and the data were analyzed with one-way ANOVA followed by Tukey post hoc comparisons between all samples. Data analysis was conducted using SPSS Version 21.
Results: The Naringenin treatment resulted in stepwise elevation in NGF levels across various doses, and the 200 mg/kg dosage delivered nearly normal levels of NGF. The NGF measurements (pg/mL) were as follows: Group I – 11.5 ± 0.5, Group II – 4.0 ± 0.5, Group III – 9.2 ± 0.5, Group IV – 7.6 ± 0.5, and Group V – 9.7 ± 0.5. The therapeutic function of Naringenin to counteract neurotrophic deficits caused by inflammation finds support from these observed improvements.
Conclusion: The in vivo psychiatric care models reveal the neurotherapeutic potential of naringenin, because it fights neuroinflammation and restores NGF levels to normal
